Voyager Therapeutics Inc (VYGR)
8.925
+0.12
(+1.31%)
USD |
NASDAQ |
May 06, 16:00
8.925
0.00 (0.00%)
After-Hours: 16:35
Voyager Therapeutics Revenue (Quarterly): 90.06M for Dec. 31, 2023
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 90.06M |
| September 30, 2023 | 4.614M |
| June 30, 2023 | 4.853M |
| March 31, 2023 | 150.48M |
| December 31, 2022 | -1.55M |
| September 30, 2022 | 41.09M |
| June 30, 2022 | 0.712M |
| March 31, 2022 | 0.658M |
| December 31, 2021 | 28.07M |
| September 30, 2021 | 1.482M |
| June 30, 2021 | 1.357M |
| March 31, 2021 | 6.501M |
| December 31, 2020 | 6.537M |
| September 30, 2020 | 117.84M |
| June 30, 2020 | 28.68M |
| March 31, 2020 | 18.07M |
| December 31, 2019 | 32.67M |
| September 30, 2019 | 20.43M |
| Date | Value |
|---|---|
| June 30, 2019 | 46.09M |
| March 31, 2019 | 5.197M |
| December 31, 2018 | 2.008M |
| September 30, 2018 | 2.094M |
| June 30, 2018 | 2.575M |
| March 31, 2018 | 0.942M |
| December 31, 2017 | 6.345M |
| September 30, 2017 | 1.148M |
| June 30, 2017 | 1.177M |
| March 31, 2017 | 1.464M |
| December 31, 2016 | 2.362M |
| September 30, 2016 | 3.308M |
| June 30, 2016 | 3.72M |
| March 31, 2016 | 4.83M |
| December 31, 2015 | 4.937M |
| September 30, 2015 | 4.937M |
| June 30, 2015 | 4.884M |
| March 31, 2015 | 2.576M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
-1.55M
Minimum
Dec 2022
150.48M
Maximum
Mar 2023
31.51M
Average
18.07M
Median
Mar 2020
Revenue (Quarterly) Benchmarks
| Ligand Pharmaceuticals Inc | 28.10M |
| United Therapeutics Corp | 677.70M |
| MEI Pharma Inc | -- |
| Agios Pharmaceuticals Inc | 7.103M |
| Macrogenics Inc | 9.164M |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | 56.40M |
| Total Expenses (Quarterly) | 36.00M |
| EPS Diluted (Quarterly) | 1.19 |
| Enterprise Value | 248.29M |
| Profit Margin (Quarterly) | 62.62% |
| Earnings Yield | 33.95% |
| Operating Earnings Yield | 30.38% |
| Normalized Earnings Yield | 33.95 |